Oncology Stream

- 腫瘤治療 -

Advancing Antibody Therapeutics to the Clinic

The Oncology Stream at PEGS is back to share what is new in the fight against cancer, and the antibody developments that are leading the charge. Drug discovery in oncology has relied on antibodies as a tool to determine therapeutic success. Bispecific antibodies and cell engagers, as well as antibody-drug conjugates are all utilized to improve targeted therapy and drug delivery. This year, we will look at how these impact the clinical journey from discovery to trials, whether single agent or combinations. We will investigate the role of the tumor microenvironment and microbiome, and what is next on the horizon in biologic development in oncology.

5月4-5日

Antibodies for Cancer Therapy
( 癌症治療抗體 )

5月6-7日

Advancing Bispecific Antibodies and Combination Therapy to the Clinic
( 推動雙特異性抗體和並用療法進入臨床 )

5月7-8日

Clinical Progress of Antibody-Drug Conjugates
( 抗體藥物複合體的臨床開發進展 )


Keynote Speakers:

Rakesh Dixit, DAPT, PhD President & CEO, Bionavigen


Paul Parren, PhD Executive Vice President, Head, R&D, Lava Therapeutics B.V.


Pablo Umaña, PhD Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich (Roche Glycart AG

Choose your language
Chinese
Japanese
Korean
English





顯示切換



免費電子郵件通知服務